351 related articles for article (PubMed ID: 23818496)
1. MET: a critical player in tumorigenesis and therapeutic target.
Graveel CR; Tolbert D; Vande Woude GF
Cold Spring Harb Perspect Biol; 2013 Jul; 5(7):. PubMed ID: 23818496
[TBL] [Abstract][Full Text] [Related]
2. c-Met: structure, functions and potential for therapeutic inhibition.
Ma PC; Maulik G; Christensen J; Salgia R
Cancer Metastasis Rev; 2003 Dec; 22(4):309-25. PubMed ID: 12884908
[TBL] [Abstract][Full Text] [Related]
3. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.
Maulik G; Shrikhande A; Kijima T; Ma PC; Morrison PT; Salgia R
Cytokine Growth Factor Rev; 2002 Feb; 13(1):41-59. PubMed ID: 11750879
[TBL] [Abstract][Full Text] [Related]
4. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
5. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Christensen JG; Burrows J; Salgia R
Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
[TBL] [Abstract][Full Text] [Related]
6. Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin-mediated prostatic tumorigenesis.
Aldahl J; Mi J; Pineda A; Kim WK; Olson A; Hooker E; He Y; Yu EJ; Le V; Lee DH; Geradts J; Sun Z
J Biol Chem; 2020 Jan; 295(2):631-644. PubMed ID: 31819003
[TBL] [Abstract][Full Text] [Related]
7. Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.
Mi J; Hooker E; Balog S; Zeng H; Johnson DT; He Y; Yu EJ; Wu H; Le V; Lee DH; Aldahl J; Gonzalgo ML; Sun Z
J Biol Chem; 2018 Dec; 293(52):20123-20136. PubMed ID: 30401749
[TBL] [Abstract][Full Text] [Related]
8. The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.
Maroun CR; Rowlands T
Pharmacol Ther; 2014 Jun; 142(3):316-38. PubMed ID: 24384534
[TBL] [Abstract][Full Text] [Related]
9. Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review).
Moriyama T; Kataoka H; Koono M; Wakisaka S
Int J Mol Med; 1999 May; 3(5):531-6. PubMed ID: 10202187
[TBL] [Abstract][Full Text] [Related]
10. Met activation and receptor dimerization in cancer: a role for the Sema domain.
Wickramasinghe D; Kong-Beltran M
Cell Cycle; 2005 May; 4(5):683-5. PubMed ID: 15846105
[TBL] [Abstract][Full Text] [Related]
11. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review).
To CT; Tsao MS
Oncol Rep; 1998; 5(5):1013-24. PubMed ID: 9683803
[TBL] [Abstract][Full Text] [Related]
12. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
Webb CP; Hose CD; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude GF
Cancer Res; 2000 Jan; 60(2):342-9. PubMed ID: 10667586
[TBL] [Abstract][Full Text] [Related]
13. The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair.
Fan S; Ma YX; Gao M; Yuan RQ; Meng Q; Goldberg ID; Rosen EM
Mol Cell Biol; 2001 Aug; 21(15):4968-84. PubMed ID: 11438654
[TBL] [Abstract][Full Text] [Related]
14. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.
Abounader R; Ranganathan S; Lal B; Fielding K; Book A; Dietz H; Burger P; Laterra J
J Natl Cancer Inst; 1999 Sep; 91(18):1548-56. PubMed ID: 10491431
[TBL] [Abstract][Full Text] [Related]
15. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.
Tiran Z; Oren A; Hermesh C; Rotman G; Levine Z; Amitai H; Handelsman T; Beiman M; Chen A; Landesman-Milo D; Dassa L; Peres Y; Koifman C; Glezer S; Vidal-Finkelstein R; Bahat K; Pergam T; Israel C; Horev J; Tsarfaty I; Ayalon-Soffer M
Clin Cancer Res; 2008 Jul; 14(14):4612-21. PubMed ID: 18628476
[TBL] [Abstract][Full Text] [Related]
16. Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells.
Parr C; Jiang WG
Int J Oncol; 2001 Oct; 19(4):857-63. PubMed ID: 11562767
[TBL] [Abstract][Full Text] [Related]
17. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis.
You WK; McDonald DM
BMB Rep; 2008 Dec; 41(12):833-9. PubMed ID: 19123972
[TBL] [Abstract][Full Text] [Related]
18. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.
Wang X; Le P; Liang C; Chan J; Kiewlich D; Miller T; Harris D; Sun L; Rice A; Vasile S; Blake RA; Howlett AR; Patel N; McMahon G; Lipson KE
Mol Cancer Ther; 2003 Nov; 2(11):1085-92. PubMed ID: 14617781
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of MET receptor dimerization by the bacterial invasion protein InlB and the HGF/SF splice variant NK1.
Niemann HH
Biochim Biophys Acta; 2013 Oct; 1834(10):2195-204. PubMed ID: 23123275
[TBL] [Abstract][Full Text] [Related]
20. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
Comoglio PM
EXS; 1993; 65():131-65. PubMed ID: 8380735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
